Ampligen(R) Blocks Critical Ebola Viral Disease (EVD)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which is Linked to High Mortality in Man

PHILADELPHIA, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen® can successfully bind to the lethal EVD viral protein designated VP35 . VP35 protein normally inactivates a patient's immune/antiviral system by binding to viral dsRNA thereby sequestering a critical antiviral/immune activator of the body which leads to high morbidity and death rates. Ampligen® competes with viral dsRNA for VP35 binding and is consistent with recent studies at USAMRIID demonstrating that Ampligen® inhibits Ebola virus infectivity in vitro. The inhibitory concentration of 4 µg/ ml at 50% viral protection is similar to the VP35 binding result showing Ampligen® binds to VP35 and displaces the viral dsRNA with a 50% inhibition at 1.1 µg/ml. These experiments establish the scientific foundation for Ampligen®, an experimental drug, as a potential preventive and early onset therapeutic for Ebola.

The Cagliari University laboratory director, Professor E. Tramontano, is a recognized expert on the dsRNA interaction with Zaire Ebola virus (EBOV) VP35 ( Antiviral Research 93:354-363, 2012). VP35 is a multifunctional protein that is indispensable for EBOV replication and, among the VP35 functions, dsRNA binding is most important in the context of EBOV pathogenesis. For example, mutations in its dsRNA binding domain cause greatly attenuated virus growth rates and loss of Ebola virulence ( J Virology 84:3004-3015, 2010).

It is believed that one potentially suitable EBOV medical countermeasure may be to impair viral replication in such a manner to allow innate and adaptive immune responses to clear the Ebola infection. This strategy could thus be advanced by targeting the VP35 dsRNA interaction by use of Ampligen®, an experimental therapeutic, which has already been used in over 1,000 non-Ebola patients and has been generally well-tolerated clinically on repeat dosing schedules as would likely be required in life-threatening clinical situations.

The experimental outcome achieved by the Cagliari University is consistent with recent predictions published in the Nature group Emerging Microbes and Infections (3, e77; doi:10.1038/emi.2014.77; published online 29 October 2014) by affiliates of Hemispherx.

Another recent US government research report observed that the inhibiting concentration (EC50) of Ampligen® for Ebola was very low relative to the Ampligen® serum levels achievable in humans ( Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon® and Ampligen® Against the Ebola Virus… Initial Ebola Studies of Alferon® and Ampligen® at USAMRIID Show Protective Activity of Both Compounds at Low Concentrations http://www.hemispherx.net/content/investor/de...p?goto=805 ). Together, the two recent reports set the stage for accelerated clinical development of Ampligen® for prevention and treatment of EVD.

The Cagliari University's in vitro study was supported by a research grant to the University by Hemispherx Biopharma. The University designed, executed and analyzed the experimentation independent of any Hemispherx suggestions regarding the conduct of experiments.

Critical Role of VP35 in High Death Rates

VP35 is a multifunctional major virulence protein that is indispensable for EBOV replication. Double-stranded RNA (dsRNA) is a necessary component of Ebola viral replication, which initiates systemic signaling cascades that normally activate interferon (IFN) regulatory factors leading to the production of IFN-α/β (type I IFNs). VP35 inhibition of dsRNA effectively disarms essential components of the innate immune response. VP35 binds to dsRNA in a sequence-independent manner, resulting in the suppression of multiple steps in the IFN signaling cascade, which otherwise would provide a broad antiviral state by activation of both the innate and adaptive arms of the immune response. Multiple investigators have demonstrated that VP35 binds dsRNA ( Antiviral Res 93:354-363, 2012) and molecular crystallographic analysis has demonstrated that binding in part is achieved by non-covalent bonding with the dsRNA phosphodiester backbone and thus shielding the viral produced dsRNA from host antiviral signaling pathways ( Nat Struct Mol Biol 17:165-173, 2010). The inavailability of viral produced dsRNA during replication results in an increased virus load and its consequences. Thus, the VP35 dsRNA interaction is an ideal target for antiviral interruption of EBOV, potentially ameliorating the pathogenesis of EVD.

Therapeutic dsRNA May Be Able to Overcome the Lethal dsRNA Sequestration Action of VP35 and Reverse the "dsRNA Deficiency" Associated with Ebola

Various forms of dsRNA have been studied as inducers of type I IFNs. Although the original dsRNA studied for efficacy in humans, poly I:poly C, was found to induce serious adverse events in humans that limited pharmaceutical development, several derivatives have survived the rigors of animal and clinical testing. Poly I:Poly C 12 U (rintatolimod, Ampligen®) was designed as an IFN inducer with a markedly reduced incidence of adverse events compared to the parent compound poly I:poly C and has demonstrated antiviral activity against a wide variety of DNA and RNA viruses in pre-clinical testing, including SARS (Severe Acute Respiratory Syndrome). Multiple mechanisms may be involved in the antiviral activity of rintatolimod in its predicted EBOV utility. These include direct induction of innate immunity as a TLR3 agonist, competition for VP35 binding with dsRNA (the conclusion of the Cagliari study reported above) allowing activation of innate immune responses, and/or serving as a required dsRNA cofactor for IFN induced enzymes that function in the innate immune cascades triggered by viral infections. In contrast to drugs under intensive development to help contain this global crisis, sequestration of dsRNA by VP35 is non-sequence dependent. Since EBOV has been demonstrated to be mutating rapidly in this epidemic ( Science 345:1369-1372, 2014), anti-EBOLA agents that depend on sequence maintenance (vaccines, monoclonal antibodies, active site viral enzyme inhibitors) may be at risk following clinical development even with crisis activated reductions in regulatory requirements.

Evidence Based Experimental Therapeutics and Global Ethical Standards for Clinical Research

The use of experimental pharmaceuticals such as Alferon® N and Ampligen® developed well beyond phase I in FDA-sanctioned clinical trials and with established safety profiles, could be advanced quickly for open-label clinical testing and analysis of efficacy. The use of potential drugs already in clinical trials also helps ensure a reliable immediate supply of clinical- grade drugs, which removes the ethical dilemma of patient selection for treatment ( New England J Med 371:1086-1089, 2014). In third world countries, with limited facilities for medical intervention, protecting the individual from exposure to Ebola containing bodily fluids may also be achieved by heightening immunity on the majority of mucosal surfaces, as by the potential use of intranasal sprays of Ampligen® or Alferon® N delivered orally (Alferon® LDO). Hemispherx is working with regulatory authorities in both the U.S. and West Africa to advance testing of these options and to potentially inhibit further escalation of this global crisis.

On September 29, 2014, Hemispherx announced a series of collaborations designed to determine the potential effectiveness of Alferon® N and Ampligen® as potential preventative and/or therapeutic treatments for Ebola related disorders ( http://www.hemispherx.net/content/investor/de...p?goto=800 ). Laboratory experiments do not necessarily indicate clinical benefit. Some of the bioterror research both past and present has been, and may in the future be, sponsored in part by contracts or grants from Hemispherx Biopharma to various independent research entities.

Hemispherx's Anti-Ebola Drug Platform

The two platform drugs of Hemispherx, Alferon® N and Ampligen®, have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. First, both drugs have mechanisms of action which are multifaceted by working thru cellular "molecular cascades" (i.e. multiple mediators which protect cells from viral pathogenesis) rather than target viral targets whose specificity is vulnerable to mutational change. Cellular antiviral pathways of innate immunity are not subject to the mutational pressures of rapidly dividing viruses, which suggests that - even in the face of viral mutation - products activating innate immunity may continue to show biological activity. For example, work at the Japanese National Institutes of Health ( Journal of Infectious Diseases 196:1313-1320,2007) indicated that Ampligen® affords wider cross-clade protection apparently through epitope expansion when added to existing influenza vaccines, an observation which has recently been extended clinically at the University of Alabama Clinical Research Center ( Vaccine 32:5490-5495, 2014) http://dx.doi.org/10.1016/j.vaccine.2014.07.078 ). Secondly, both drugs are unusually effective in vitro against highly virulent viruses such as SARS, as noted by Singapore investigators ( Emerging Infectious Disease 10(4):581-586, 2004) and independent US health researchers ( Virology 395:210-222, 2009). Alferon® N has also demonstrated superior in vitro potency to that shown by recombinant alpha interferons ( AIDS Research and Human Retroviruses 9:1115-1122, 1993) and ability to afford apparent clinical benefit in the presence of antibodies against recombinant interferons ( Journal of Interferon and Cytokine Research 32:95-102, 2012). Ampligen® is also active in vitro against the Respiratory Syncytial Virus (RSV) which is organized in a pattern very similar to EBOV genome and both the viruses are "negative sense" RNA viruses.

Comparison with Medical Countermeasures Presuming Genetically Stable Pandemic Viruses as Drug Targets

The Wall Street Journal ( WSJ ) (September 20-21, 2014), proposed that based on new cases multiplying in Liberia, Guinea, Sierra Leone, Nigeria and Senegal, the Ebola epidemic "foreshadows threats that will strike the US". This prediction proved correct. As of November 5, 2014, some 4,818 people have died, according to the World Health Organization (WHO). The WSJ article summarizes certain US readiness improvements since the year 2004 passage of Project Bioshield, including a large basic and translational research portfolio built by NIH and the Pentagon. Moreover, the majority of the specialized countermeasures within the existing portfolio implicitly assume that the viral targets will be immutable or stationary in their molecular configurations, thus providing relatively stable viral targets for drug development. However, similar assumptions made several years ago on the cusp of global preparation for a possible influenza pandemic proved to be largely incorrect; the ongoing genomic surveillance of Ebola in the year 2014 outbreak appears to be following a similar course by demonstrating genetic mutation/instability which may make many "designer" drugs (monoclonal antibodies, short interfering RNAs) largely ineffective despite promising preclinical results to date.

About Alferon® N and Alferon® LDO

Alferon® N is the only natural source, multi-species alpha interferon currently approved for sale in the U.S. Alferon® N is approved in the U.S. only for the treatment of refractory or recurring external genital warts caused by human papilloma virus in patients 18 years of age or older.

Clinical trial data will be necessary to establish the human efficacy of Alferon® N for EVD.  Alferon® LDO is an experimental low dose form of Alferon® which can be delivered orally; Alferon® LDO was recently shown to be able to prevent viral induced lung pathology in primates exposed to pandemic influenza H5N1 ( Antiviral Research 110:175–180, 2014).

About Ampligen®

Ampligen®, an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.

Ebola virus specifically inhibits the dsRNA within cells via a sequestration process.  Such RNA would otherwise cause a robust antiviral response to be mounted. Ampligen® may be able to overcome this deficiency in host response. Clinical trial data will be necessary to establish the human efficacy of Ampligen® for Ebola virus.

About USAMRIID

Since 1969, USAMRIID has served as the Department of Defense's (DoD) lead laboratory for medical biological defense research. While its core mission is to protect the warfighter from biological threats, it also investigates disease outbreaks and threats to public health. Research conducted at USAMRIID leads to medical solutions—therapeutics, vaccines, diagnostics, and information—that benefit both military personnel and civilians. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

About The University of Cagliari and its history

The University of Cagliari is a public state University and has about 31,102 enrolled students, over 1,000 teaching staff and more than 1,000 professionals at the technical-administrative staff.

At the moment the University of Cagliari is one of the largest enterprises in the Region of Sardinia, thanks to its international policy, studies and its numerous agreements with prestigious universities in Europe and around the world.

The Studium Generalis Kalaritanum was founded in 1606 along the lines of the old Spanish Universities of Salamanca, Valladolid and Lérida.  It originally offered Law, Latin, Greek and Hebrew Literature, the Liberal Arts, Medicine, Surgery, Philosophy and Science. The 19th and 20th centuries saw more and more emphasis placed on research activities, with the achievement of important, internationally acclaimed results, especially in the fields of Medicine, Physics, Chemistry, Biology and Archaeology. The largest campus is situated in Monserrato, on an area of 73 hectares. It hosts the science faculties, many departments with their respective faculties, and one of the University general hospitals, appropriately integrated with other medical institutions. The Department of Life and Environmental Science groups together more than 80 professors of the Biological and Chemical areas. In particular, the Biomedical Section, where the Laboratory of Prof. Tramontano is located, is composed by professors of Biochemistry and Microbiology.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.  For more information please visit www.hemispherx.net .

Disclosure Notice

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. The final results of these efforts and/or any other activities could vary materially from Hemispherx's expectations. In vitro experiments are not necessarily predictive of clinical outcome and no representations are made that any products described in this release will be ultimately determined safe and effective in the prevention and/or treatment of the Ebola virus. Moreover, it would take time, testing and funds to obtain approval of any such product and there are no assurances that a commercial approval for treatment of the Ebola virus can be obtained.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "potential," "potentially," "possible," and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.

Company/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 128

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 197

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 107

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 37

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 237

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading

Top 5 Most Recently Viewed Articles

Tarkett Updates on Voting Rights and Share Capital Structure

Updated Category News Views 57

Tarkett's Current Voting Rights and Share Capital The information regarding Tarkett’s share capital and the total number of voting rights reflects vital details for investors and stakeholders. As of the designated date, Tarkett boasts a significant total number of shares that contribute to its economic activities. Understanding Voting Rights in Tarkett As a significant...

Continue Reading
Quiddity Engineering Welcomes Ryan Quinn as New GM in Texas

Updated Category News Views 267

Quiddity Engineering Introduces Ryan Quinn, PE, as General Manager Quiddity Engineering is thrilled to share the news of Ryan Quinn, PE, joining the team as the General Manager for its Central Texas region. This appointment signifies a key strategic move for the organization, as Ryan brings over 18 years of invaluable experience in the consulting engineering landscape....

Continue Reading
Pure Roofing Unveils Innovative Office Space Focused on Growth

Updated Category News Views 206

Pure Roofing Launches New Office to Elevate Employee Culture Pure Roofing has recently expanded by opening a new office, reflecting a commitment to employee well-being and community engagement. Featuring a unique design that includes an indoor basketball court, this innovative space aims to enhance teamwork, productivity, and wellness among staff. The establishment of...

Continue Reading
Crown Point Energy Reports Q3 Financial Performance Highlights

Updated Category News Views 207

Crown Point Energy Announces Financial Results for Q3 Crown Point Energy Inc. recently shared its operating and financial results for the period ending September 30, 2024. These insights reflect the company’s performance amidst varied market conditions. Financial Overview of Q3 2024 In Q3 2024, Crown Point faced several challenges but also solid achievements: Reported a...

Continue Reading
Empowering Financial Innovation: Semifinalists of 2024 Edition

Updated Category News Views 125

Milken-Motsepe Prize in FinTech Announces Semifinalists The Milken Institute and the Motsepe Foundation have revealed the 10 standout teams that have advanced to the Semifinalist Round of the prestigious Milken-Motsepe Prize in FinTech, each securing $100,000 in funding to fuel their innovative projects. Driving Financial Inclusion Through Innovation This esteemed prize...

Continue Reading